OTCMKTS:RGRX RegeneRx Biopharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.16 +0.01 (+6.56%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.16▼$0.1850-Day Range$0.15▼$0.2252-Week Range$0.10▼$0.45Volume67,399 shsAverage Volume30,286 shsMarket Capitalization$23.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest RegeneRx Biopharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.31 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for RegeneRx Biopharmaceuticals. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.06% of the outstanding shares of RegeneRx Biopharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneRx Biopharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in RegeneRx Biopharmaceuticals has recently decreased by 15.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneRx Biopharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneRx Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGRX. Previous Next 1.1 News and Social Media Coverage News SentimentRegeneRx Biopharmaceuticals has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RegeneRx Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of RegeneRx Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.15% of the stock of RegeneRx Biopharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) StockRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.Read More RGRX Stock News HeadlinesJune 22, 2022 | finance.yahoo.comRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259May 4, 2022 | finance.yahoo.comTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaFebruary 11, 2022 | finance.yahoo.comRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthFebruary 7, 2022 | nasdaq.comRGRX Real-Time QuotesJanuary 25, 2022 | finance.yahoo.comResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryJanuary 20, 2022 | nasdaq.comRGRX After-Hours QuotesJanuary 12, 2022 | seekingalpha.comMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateDecember 17, 2021 | finance.yahoo.comRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022November 29, 2021 | finance.yahoo.comRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromeOctober 29, 2021 | finance.yahoo.comClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingOctober 6, 2021 | finance.yahoo.comResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with SepsisOctober 5, 2021 | finance.yahoo.comNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's DiseaseSeptember 27, 2021 | finance.yahoo.comRegeneRx Licensee Acquired by Korean Biopharmaceutical GroupJuly 22, 2021 | finance.yahoo.comRegeneRx Issues Letter To StockholdersJuly 14, 2021 | finance.yahoo.comRegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye SyndromeJuly 1, 2021 | finance.yahoo.comRegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private PlacementMay 14, 2021 | finance.yahoo.comRegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye SyndromeMarch 22, 2021 | finance.yahoo.comRegeneRx Issues Update on ARISE-3 TrialMarch 18, 2021 | finance.yahoo.comRegeneRx Reports Topline Results of ARISE-3 Dry Eye TrialFebruary 24, 2021 | markets.businessinsider.comRegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye TrialJanuary 28, 2021 | seekingalpha.comRegeneRx addresses rumors regarding late-stage dry eye trialJanuary 26, 2021 | finance.yahoo.comRegeneRx Comments on ARISE-3 Clinical TrialDecember 21, 2020 | finance.yahoo.comRegeneRx Issues Year End Letter To StockholdersNovember 9, 2020 | finance.yahoo.comLast Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical TrialOctober 28, 2020 | finance.yahoo.comRegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye TrialSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RGRX Previous SymbolOTC:RGRX CUSIPN/A CIK707511 Webwww.regenerx.com Phone(301) 208-9191Fax301-280-1996Employees3Year FoundedN/ACompany Calendar Today7/06/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,600,000.00 Net Margins-2,149.78% Pretax Margin-2,149.78% Return on EquityN/A Return on Assets-110.37% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$80,000.00 Price / Sales291.59 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-8.13Miscellaneous Outstanding Shares143,550,000Free Float125,606,000Market Cap$23.33 million OptionableNot Optionable Beta0.38 RegeneRx Biopharmaceuticals Frequently Asked Questions How has RegeneRx Biopharmaceuticals' stock performed in 2022? RegeneRx Biopharmaceuticals' stock was trading at $0.16 at the start of the year. Since then, RGRX stock has increased by 1.6% and is now trading at $0.1625. View the best growth stocks for 2022 here. Who are RegeneRx Biopharmaceuticals' key executives? RegeneRx Biopharmaceuticals' management team includes the following people: Dr. Allan L. Goldstein Ph.D., Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board (Age 84, Pay $90k)Mr. J. J. Finkelstein, Pres, CEO & Director (Age 70, Pay $83.38k)Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs Who are some of RegeneRx Biopharmaceuticals' key competitors? Some companies that are related to RegeneRx Biopharmaceuticals include BriaCell Therapeutics (BCTX), Cue Biopharma (CUE), Checkpoint Therapeutics (CKPT), Anixa Biosciences (ANIX), Fortress Biotech (FBIO), Eliem Therapeutics (ELYM), Ardelyx (ARDX), Xilio Therapeutics (XLO), Capricor Therapeutics (CAPR), Seelos Therapeutics (SEEL), Adagene (ADAG), Galectin Therapeutics (GALT), Enlivex Therapeutics (ENLV), TherapeuticsMD (TXMD) and Alzamend Neuro (ALZN). View all of RGRX's competitors. What other stocks do shareholders of RegeneRx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), Inpixon (INPX), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA). What is RegeneRx Biopharmaceuticals' stock symbol? RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX." How do I buy shares of RegeneRx Biopharmaceuticals? Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RegeneRx Biopharmaceuticals' stock price today? One share of RGRX stock can currently be purchased for approximately $0.16. How much money does RegeneRx Biopharmaceuticals make? RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) has a market capitalization of $23.33 million and generates $80,000.00 in revenue each year. How many employees does RegeneRx Biopharmaceuticals have? RegeneRx Biopharmaceuticals employs 3 workers across the globe. How can I contact RegeneRx Biopharmaceuticals? RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The official website for RegeneRx Biopharmaceuticals is www.regenerx.com. The biopharmaceutical company can be reached via phone at (301) 208-9191, via email at info@regenerx.com, or via fax at 301-280-1996. This page (OTCMKTS:RGRX) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
